
https://www.facingourrisk.org/research-clinical-trials/study/267 /observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
https://www.facingourrisk.org/research-clinical-trials/study/271 /a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)
Prevention
Prevention study for women at high risk for ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/245 /a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)
Treatment
Phase 2 treatment study for recurrent endometrial cancer
https://www.facingourrisk.org/research-clinical-trials/study/281 /studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05411718 (https://clinicaltrials.gov/show/NCT05411718)
Prevention
Prevention study for people with Lynch syndrome
https://www.facingourrisk.org/research-clinical-trials/study/255 /kindred
Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation
https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)
Treatment
Cancer treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
https://www.facingourrisk.org/research-clinical-trials/study/240 /metastatic-castration-resistant-prostate-cancer-clinical-trial
Clinicaltrials.gov identifier:
NCT03460977 (https://clinicaltrials.gov/show/NCT03460977)
Treatment
Treatment study for men with metastatic castration resistant prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/230 /treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)
Treatment
Treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/140 /olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04858334 (https://clinicaltrials.gov/show/NCT04858334)
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/180 /prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)
Prevention
People at high risk for prostate cancer due to an inherited mutation
https://www.facingourrisk.org/research-clinical-trials/study/210 /treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra
Clinicaltrials.gov identifier:
NCT04038502 (https://clinicaltrials.gov/show/NCT04038502)
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
https://www.facingourrisk.org/research-clinical-trials/study/141 /blood-markers-of-early-pancreas-cancer
Clinicaltrials.gov identifier:
NCT03568630 (https://clinicaltrials.gov/show/NCT03568630)
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk
https://www.facingourrisk.org/research-clinical-trials/study/250 /helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Clinicaltrials.gov identifier:
NCT05483283 (https://clinicaltrials.gov/show/NCT05483283)
Prevention
Latinas with a high risk of breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/259 /upright-mri-for-prostate-cancer-screening
Clinicaltrials.gov identifier:
NCT03474913 (https://clinicaltrials.gov/show/NCT03474913)
Prevention
Screening for prostate cancer using upright MRI
https://www.facingourrisk.org/research-clinical-trials/study/169 /brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences
Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing
https://www.facingourrisk.org/research-clinical-trials/study/248 /cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.